Biopharmx Corp Stock Price, News & Analysis (NYSEAMERICAN:BPMX)

$0.19 0.00 (0.00 %)
(As of 11/20/2017 12:23 PM ET)
Previous Close$0.19
Today's Range$0.18 - $0.20
52-Week Range$0.16 - $0.90
Volume940,300 shs
Average Volume1.34 million shs
Market Capitalization$15.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51

About Biopharmx Corp (NYSEAMERICAN:BPMX)

Biopharmx Corp logoBioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: N/A
  • Symbol: NYSEAMERICAN:BPMX
  • Previous Symbol: NYSE:BPMX
  • CUSIP: N/A
  • Web: www.biopharmx.com
Profitability:
  • Trailing EPS: ($0.34)
  • Net Margins: -22,005.88%
  • Return on Equity: -5,749.08%
  • Return on Assets: -240.31%
Misc:
  • Outstanding Shares: 79,670,000
 

Frequently Asked Questions for Biopharmx Corp (NYSEAMERICAN:BPMX)

What is Biopharmx Corp's stock symbol?

Biopharmx Corp trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

How were Biopharmx Corp's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) released its earnings results on Wednesday, September, 13th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.06). The biotechnology company earned $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%. View Biopharmx Corp's Earnings History.

When will Biopharmx Corp make its next earnings announcement?

Biopharmx Corp is scheduled to release their next quarterly earnings announcement on Tuesday, December, 12th 2017. View Earnings Estimates for Biopharmx Corp.

Where is Biopharmx Corp's stock going? Where will Biopharmx Corp's stock price be in 2017?

3 analysts have issued 1 year price targets for Biopharmx Corp's shares. Their forecasts range from $1.50 to $3.00. On average, they expect Biopharmx Corp's stock price to reach $2.50 in the next twelve months. View Analyst Ratings for Biopharmx Corp.

Are investors shorting Biopharmx Corp?

Biopharmx Corp saw a increase in short interest in October. As of October 31st, there was short interest totalling 4,599,284 shares, an increase of 7.7% from the October 13th total of 4,271,767 shares. Based on an average daily trading volume, of 1,541,571 shares, the short-interest ratio is currently 3.0 days. Approximately 8.0% of the company's shares are sold short.

Who are some of Biopharmx Corp's key competitors?

Who are Biopharmx Corp's key executives?

Biopharmx Corp's management team includes the folowing people:

  • James R. Pekarsky, Chairman of the Board, Chief Executive Officer (Age 55)
  • Anja B. Krammer, President, Director (Age 47)
  • Gregory David Kitchener, Chief Financial Officer, Executive Vice President - Finance
  • Kin F. Chan Ph.D., Executive Vice President - Research & Development (Age 41)
  • AnnaMarie Daniels, Executive Vice President - Clinical and Regulatory Affairs
  • Stephen Morlock, Independent Director (Age 61)
  • Charles Gregory Vontz, Independent Director (Age 55)
  • Ping Wang, Independent Director (Age 38)

How do I buy Biopharmx Corp stock?

Shares of Biopharmx Corp can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biopharmx Corp's stock price today?

One share of Biopharmx Corp stock can currently be purchased for approximately $0.19.

How big of a company is Biopharmx Corp?

Biopharmx Corp has a market capitalization of $15.14 million.

How can I contact Biopharmx Corp?

Biopharmx Corp's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.


MarketBeat Community Rating for Biopharmx Corp (NYSEAMERICAN BPMX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about Biopharmx Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Biopharmx Corp (NYSEAMERICAN:BPMX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50

Consensus Price Target History for Biopharmx Corp (NYSEAMERICAN:BPMX)

Price Target History for Biopharmx Corp (NYSEAMERICAN:BPMX)

Analysts' Ratings History for Biopharmx Corp (NYSEAMERICAN:BPMX)

Show:
DateFirmActionRatingPrice TargetDetails
9/19/2017HC WainwrightReiterated RatingBuy$3.00View Rating Details
9/13/2017Maxim GroupLower Price TargetBuy$3.00 -> $1.50View Rating Details
6/3/2017Roth CapitalSet Price TargetBuy$3.00View Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Biopharmx Corp (NYSEAMERICAN:BPMX)

Earnings by Quarter for Biopharmx Corp (NYSEAMERICAN:BPMX)

Earnings History by Quarter for Biopharmx Corp (NYSEAMERICAN BPMX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/12/2017        
9/13/2017Q2 2018($0.06)($0.06)$0.02 million$0.02 millionViewN/AView Earnings Details
6/13/2017Q1 2018($0.07)($0.07)$0.03 million$0.02 millionViewN/AView Earnings Details
12/13/2016Q3 2017($0.15)($0.13)ViewN/AView Earnings Details
6/14/2016Q117($0.17)($0.16)ViewListenView Earnings Details
4/26/2016Q416($0.17)($0.18)ViewListenView Earnings Details
12/14/2015Q316($0.19)($0.17)ViewN/AView Earnings Details
9/14/2015Q216($0.29)($0.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biopharmx Corp (NYSEAMERICAN:BPMX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Biopharmx Corp (NYSEAMERICAN:BPMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biopharmx Corp (NYSEAMERICAN BPMX)

Insider Trades by Quarter for Biopharmx Corp (NYSEAMERICAN:BPMX)

Insider Trades by Quarter for Biopharmx Corp (NYSEAMERICAN BPMX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2017Vivo Capital Viii, LlcMajor ShareholderSell296,394$0.20$59,278.80View SEC Filing  
8/1/2017Franklin Resources IncMajor ShareholderBuy250,000$0.34$85,000.00View SEC Filing  
4/28/2017Vivo Capital Fund Viii, L.P.Major ShareholderBuy1,282,052$0.78$1,000,000.56View SEC Filing  
11/28/2016Stephen MorlockDirectorBuy428,571$0.35$149,999.85View SEC Filing  
8/15/2016Franklin Resources IncMajor ShareholderBuy484,615$0.65$314,999.75View SEC Filing  
3/29/2016Franklin Resources IncMajor ShareholderBuy540,000$1.20$648,000.00View SEC Filing  
1/14/2016Stephen MorlockDirectorBuy12,000$1.52$18,240.00View SEC Filing  
1/12/2016Stephen MorlockDirectorBuy6,000$1.53$9,180.00View SEC Filing  
1/7/2016Stephen MorlockDirectorBuy5,000$1.47$7,350.00View SEC Filing  
10/15/2015Stephen MorlockDirectorBuy5,000$1.24$6,200.00View SEC Filing  
10/9/2015Stephen MorlockDirectorBuy3,000$1.21$3,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Biopharmx Corp (NYSEAMERICAN BPMX)

Source:

Social Media

Social activity is not available for this stock.

Financials

Chart

Biopharmx Corp (NYSEAMERICAN BPMX) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.